Treatment of venous thromboembolism in cancer patients

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 93-101

  Lee, Agnes Y Y ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

antiocoagulants; cancer; deep vein thrombosis; low molecular weight heparin; neoplasm; pulmonary embolism; treatment; vena cava filter; venous thromboembolism; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MONOTHERAPY; NEOPLASM; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 61649126862     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.11.001     Document Type: Review

References (51)

1. Khorana A.A., Francis C.W., Culakova E., et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5 (2007) 632-634
2. Lee A.Y. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 110 (2003) 167-172
3. Stein P.D., Beemath A., Meyers F.A., et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119 (2006) 60-68
4. Hutten B.A., Prins M.H., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 (2000) 3078-3083
5. Prandoni P., Lensing A.W.A., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Haemostasis 30 Suppl. 1 (2000) 58
6. van Dongen C.J., van den Belt A.G., Prins M.H., et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4 (2004) CD001100
7. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 Suppl. (2008) 340S-380S
8. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 Suppl. (2008) 141S-159S
9. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296 (2006) 935-942
10. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
11. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
12. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996) 677-681
13. Koopman M.M., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low- molecular-weight heparin administered at home. The Tasman Study Group. [published erratum appears in N Engl J Med 1997;337:1251]. N Engl J Med 334 (1996) 682-687
14. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 337 (1997) 657-662
15. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
16. Wells P.S., Kovacs M.J., Bormanis J., et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 158 (1998) 1809-1812
17. Harrison L., McGinnis J., Crowther M., et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 158 (1998) 2001-2003
18. O'Shaughnessy D., Miles J., and Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM 93 (2000) 663-667
19. Ageno W., Steidl L., Marchesi C., et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 87 (2002) 286-291
20. Avritscher E.B., Cantor S.B., Shih Y.C., et al. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 12 (2004) 531-536
21. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 Suppl. (2008) 454S-545S
22. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
23. Noble S.I., Hood K., and Finlay I.G. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med 21 (2007) 473-476
24. Gates S., Brocklehurst P., and Davis L.J. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2 (2002) CD001689
25. Rodger M.A., Kahn S.R., Cranney A., et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 5 (2007) 1600-1606
26. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
27. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
28. Deitcher S.R., Kessler C.M., Merli G., et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12 (2006) 389-396
29. Hull R.D., Pineo G.F., Brant R.F., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006) 1062-1072
30. Monreal M., Zacharski L., Jimenez J.A., et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2 (2004) 1311-1315
31. Baglin T.P., Keeling D.M., and Watson H.G. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 132 (2006) 277-285
32. Wagman L.D., Baird M.F., Bennett C.L., et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 838-869
33. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
34. Buller H.R., Cohen A.T., Davidson B., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007) 1094-1104
35. Buller H.R., Cohen A.T., Davidson B., et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357 (2007) 1105-1112
36. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338 (1998) 409-415
37. PREPIC Investigators. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 (2005) 416-422
38. Elting L.S., Escalante C.P., Cooksley C., et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164 (2004) 1653-1661
39. Goerner A. The influence of anticlotting agents on transplantation and growth of tumour tissue. J Lab Clin Med 16 (1930) 369-372
40. Lebeau B., Chastang C., Brechot J.M., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74 (1994) 38-45
41. Elias E.G., Shukla S.K., and Mink I.B. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 36 (1975) 129-136
42. Chahinian A.P., Propert K.J., Ware J.H., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7 (1989) 993-1002
43. Zacharski L.R., Henderson W.G., Rickles F.R., et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245 (1981) 831-835
44. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
45. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
46. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
47. Maurer L.H., Herndon J.E., Hollis D.R., et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 15 (1997) 3378-3387
48. Sideras K., Schaefer P.L., Okuno S.H., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81 (2006) 758-767
49. Zacharski L.R., Henderson W.G., Rickles F.R., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53 (1984) 2046-2052
50. Kuderer N.M., Khorana A.A., Lyman G.H., et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110 (2007) 1149-1161
51. Lazo-Langner A., Goss G.D., Spaans J.N., et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5 (2007) 729-737